Blue Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
Other funds holding ALNY
Blue Trust's ALNY Position: Q3 2026 in Review
Blue Trust reduced its Alnylam Pharmaceuticals (ALNY) stake by 73% in Q3 2026, selling an estimated $41.5K and leaving 61 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1593.
Blue Trust first reported a position in ALNY in Q2 2022 and has held it in 18 quarters since. The position peaked at $422K in Q2 2025. 633 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.
- Blue Trust held 61 shares of Alnylam Pharmaceuticals worth $15.1K as of Q3 2026.
- Blue Trust sold 163 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $41.5K.
- Alnylam Pharmaceuticals made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #1593 holding.
- Blue Trust first reported a position in Alnylam Pharmaceuticals in Q2 2022 and has held it in 18 quarters since.
- Blue Trust's Alnylam Pharmaceuticals position peaked at $422K in Q2 2025.
- 633 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.
Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.